PBH Quote, Financials, Valuation and Earnings

Abbott Laboratories has a net margin of 16.48% compared to Prestige Consumer Healthcare, Inc.'s net margin of 15.71%. Prestige Consumer Healthcare, Inc.'s return on equity of 10.21% beat Abbott Laboratories's return on equity of 12.91%.

Prestige Consumer Healthcare, Inc. has a consensus price target of $77.83, signalling upside risk potential of 12.31%. On the other hand Abbott Laboratories has an analysts' consensus of $133.39 which suggests that it could grow by 14.65%. Given that Abbott Laboratories has higher upside potential than Prestige Consumer Healthcare, Inc., analysts believe Abbott Laboratories is more attractive than Prestige Consumer Healthcare, Inc..

Prestige Consumer Healthcare, Inc. has a beta of 0.425, which suggesting that the stock is 57.452% less volatile than S&P 500. In comparison Abbott Laboratories has a beta of 0.749, suggesting its less volatile than the S&P 500 by 25.138%.

Prestige Consumer Healthcare, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Abbott Laboratories offers a yield of 2.06% to investors and pays a quarterly dividend of $0.63 per share. Prestige Consumer Healthcare, Inc. pays -- of its earnings as a dividend. Abbott Laboratories pays out 64.54% of its earnings as a dividend. Abbott Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Prestige Consumer Healthcare, Inc. quarterly revenues are $283.4M, which are smaller than Abbott Laboratories quarterly revenues of $11.5B. Prestige Consumer Healthcare, Inc.'s net income of $46.7M is lower than Abbott Laboratories's net income of $1.8B. Notably, Prestige Consumer Healthcare, Inc.'s price-to-earnings ratio is 18.33x while Abbott Laboratories's PE ratio is 31.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Prestige Consumer Healthcare, Inc. is 3.10x versus 4.59x for Abbott Laboratories. Usually stocks with elevated PS ratios are considered overvalued.

Boston Scientific Corp. has a net margin of 16.48% compared to Prestige Consumer Healthcare, Inc.'s net margin of 12.68%. Prestige Consumer Healthcare, Inc.'s return on equity of 10.21% beat Boston Scientific Corp.'s return on equity of 12.55%.

Prestige Consumer Healthcare, Inc. has a consensus price target of $77.83, signalling upside risk potential of 12.31%. On the other hand Boston Scientific Corp. has an analysts' consensus of $104.75 which suggests that it could grow by 36.31%. Given that Boston Scientific Corp. has higher upside potential than Prestige Consumer Healthcare, Inc., analysts believe Boston Scientific Corp. is more attractive than Prestige Consumer Healthcare, Inc..

Prestige Consumer Healthcare, Inc. has a beta of 0.425, which suggesting that the stock is 57.452% less volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.666, suggesting its less volatile than the S&P 500 by 33.441%.

Prestige Consumer Healthcare, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Prestige Consumer Healthcare, Inc. pays -- of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend.

Prestige Consumer Healthcare, Inc. quarterly revenues are $283.4M, which are smaller than Boston Scientific Corp. quarterly revenues of $5.3B. Prestige Consumer Healthcare, Inc.'s net income of $46.7M is lower than Boston Scientific Corp.'s net income of $670M. Notably, Prestige Consumer Healthcare, Inc.'s price-to-earnings ratio is 18.33x while Boston Scientific Corp.'s PE ratio is 39.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Prestige Consumer Healthcare, Inc. is 3.10x versus 5.72x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.

InfuSystem Holdings, Inc. has a net margin of 16.48% compared to Prestige Consumer Healthcare, Inc.'s net margin of 5.62%. Prestige Consumer Healthcare, Inc.'s return on equity of 10.21% beat InfuSystem Holdings, Inc.'s return on equity of 11.83%.

Prestige Consumer Healthcare, Inc. has a consensus price target of $77.83, signalling upside risk potential of 12.31%. On the other hand InfuSystem Holdings, Inc. has an analysts' consensus of $14.90 which suggests that it could grow by 69.9%. Given that InfuSystem Holdings, Inc. has higher upside potential than Prestige Consumer Healthcare, Inc., analysts believe InfuSystem Holdings, Inc. is more attractive than Prestige Consumer Healthcare, Inc..

Prestige Consumer Healthcare, Inc. has a beta of 0.425, which suggesting that the stock is 57.452% less volatile than S&P 500. In comparison InfuSystem Holdings, Inc. has a beta of 1.674, suggesting its more volatile than the S&P 500 by 67.352%.

Prestige Consumer Healthcare, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InfuSystem Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Prestige Consumer Healthcare, Inc. pays -- of its earnings as a dividend. InfuSystem Holdings, Inc. pays out -- of its earnings as a dividend.

Prestige Consumer Healthcare, Inc. quarterly revenues are $283.4M, which are larger than InfuSystem Holdings, Inc. quarterly revenues of $36.2M. Prestige Consumer Healthcare, Inc.'s net income of $46.7M is higher than InfuSystem Holdings, Inc.'s net income of $2M. Notably, Prestige Consumer Healthcare, Inc.'s price-to-earnings ratio is 18.33x while InfuSystem Holdings, Inc.'s PE ratio is 27.82x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Prestige Consumer Healthcare, Inc. is 3.10x versus 1.29x for InfuSystem Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Neogen Corp. has a net margin of 16.48% compared to Prestige Consumer Healthcare, Inc.'s net margin of -7.09%. Prestige Consumer Healthcare, Inc.'s return on equity of 10.21% beat Neogen Corp.'s return on equity of -25.93%.

Prestige Consumer Healthcare, Inc. has a consensus price target of $77.83, signalling upside risk potential of 12.31%. On the other hand Neogen Corp. has an analysts' consensus of $11.67 which suggests that it could grow by 3.89%. Given that Prestige Consumer Healthcare, Inc. has higher upside potential than Neogen Corp., analysts believe Prestige Consumer Healthcare, Inc. is more attractive than Neogen Corp..

Prestige Consumer Healthcare, Inc. has a beta of 0.425, which suggesting that the stock is 57.452% less volatile than S&P 500. In comparison Neogen Corp. has a beta of 1.980, suggesting its more volatile than the S&P 500 by 98.002%.

Prestige Consumer Healthcare, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Neogen Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Prestige Consumer Healthcare, Inc. pays -- of its earnings as a dividend. Neogen Corp. pays out -- of its earnings as a dividend.

Prestige Consumer Healthcare, Inc. quarterly revenues are $283.4M, which are larger than Neogen Corp. quarterly revenues of $224.7M. Prestige Consumer Healthcare, Inc.'s net income of $46.7M is higher than Neogen Corp.'s net income of -$15.9M. Notably, Prestige Consumer Healthcare, Inc.'s price-to-earnings ratio is 18.33x while Neogen Corp.'s PE ratio is 2,124.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Prestige Consumer Healthcare, Inc. is 3.10x versus 2.77x for Neogen Corp.. Usually stocks with elevated PS ratios are considered overvalued.